NEWS & MEDIA

Top 10 finalists include bio-tech, virtual reality emergency response training, electric mobility and wireless tech among others. At StemTek we’re pleased to announce that we’ve been invited to participate in the Bridge to MassChallenge Biscay 2017 boot camp in Boston this Spring. The 4-day, all expenses paid boot camp takes place at MassChallenge’s flagship office in Boston, Massachusetts from March 20 to March 23. As part of the program we’re looking forward to...
Stemtek Therapeutics has the pleasure to announce that next February 22nd and 23rd, our CEO Dr. Angel Garcia Martin will be in London attending the “3D Cell Culture” congress organized by the SMI Group. Where he will be able to meet industry and research leaders, who will also talk about the latest technologies, challenges, updates and uses of the 3D cell culture. Angel will be delighted to meet you in London, please contact agmartin@stemtektherapeutics.com

An exciting year ahead

Message from the CEO - January 03, 2017

2016 has just come to an end.  It has undoubtedly been a good year for StemTek.  Early in the year we welcome our new shareholders (Seed Capital Bizkaia, BasqueFondo and Helenes Ventures) that teamed with us to fuel the growth of the company.  2016 saw the redesign of our webpage with new spaces for communication and showcasing our technology.  In the Fall we launched our first product to the market, Cell2Sphere, a revolutionary 3D cell culture kit enriched on cancer stem ...

Cancer Stem Cells Impact on Treatment, Obergurgl

By Angel Garcia Martin - December 16, 2016

Last week I attended the Cancer Stem Cells: Impact on Treatment conference in Obergurgl, Tyrol, Austria, getting the opportunity to interface with scientists from across the cancer stem cell field. It was a great conference where the top issues associated with this exciting topic came up for fruitful discussion in an unparalleled alpine environment.  I would like to thank and acknowledge the great work of the organizers, represented by Prof. Ira Skvortsova, Innsbruck Medical University. ...
Recently StemTek was selected by the European Commission Horizon 2020 SME Instrument for being one of the top innovative SMEs in its sector. Significantly, Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding. By winning Phase I, StemTek will receive €50.000 in funding and is eligible to participate in Phase II for up to €2.5 million in funding and mentorship. With this funding our goal is to expand and ramp up scalable producti...
Back to top